

![]() |
Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women |
|
Authors | ![]() | |
Published in | Antiviral therapy. 2013, vol. 18, no. 2, p. 171-82 | |
Abstract | Physiological changes associated with pregnancy may alter antiretroviral plasma concentrations and might jeopardize prevention of mother-to-child HIV transmission. Lopinavir is one of the protease inhibitors more frequently prescribed during pregnancy in Europe. We described the free and total pharmacokinetics of lopinavir in HIV-infected pregnant and non-pregnant women, and evaluated whether significant alterations in its disposition and protein binding warrant systematic dosage adjustment. | |
Keywords | Adult — Anti-HIV Agents/administration & dosage/pharmacokinetics — Blood Proteins/metabolism — Delivery, Obstetric — Female — HIV Infections/blood/drug therapy/transmission — Humans — Lopinavir/administration & dosage/pharmacokinetics — Maternal-Fetal Exchange — Middle Aged — Orosomucoid/metabolism — Postpartum Period/blood — Pregnancy — Prospective Studies — Protein Binding — Serum Albumin/metabolism — Young Adult | |
Identifiers | DOI: 10.3851/IMP2328 PMID: 22914504 | |
Full text | ||
Structures | ||
Research group | Martinez De Tejada Begona (272) | |
Citation (ISO format) | FAYET-MELLO, Aurélie et al. Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women. In: Antiviral therapy, 2013, vol. 18, n° 2, p. 171-82. doi: 10.3851/IMP2328 https://archive-ouverte.unige.ch/unige:31943 |